Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Arthritis and Rheumatism
|
April 29, 2006
Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus
Suzanne Donnelly, Wendy Roake, Simon Brown, et al.
Arthritis Research & Therapy
|
May 30, 2019
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, et al.
Nuclear Medicine and Biology
|
February 17, 2012
Synthesis of ApoSense compound [18F]2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-(fluoromethyl)butanoic acid ([18F]NST732) by nucleophilic ring opening of an aziridine precursor
Falguni Basuli, Haitao Wu, Zhen-Dan Shi, et al.
Frontiers in Medicine
|
June 12, 2023
Characteristics of delirium and its association with sedation and in-hospital mortality in patients with COVID-19 on veno-venous extracorporeal membrane oxygenation
Philip Young-Woo Sun, Jonathon Fanning, Anna Peeler, et al.
Plos One
|
April 14, 2018
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
Edgar Turner Overton, Steven J Lawrence, Eva Wagner, et al.
Research and Practice in Thrombosis and Haemostasis
|
December 19, 2022
Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients
Philip Young-Ill Choi, Danny Hsu, Huyen Anh Tran, et al.
Plos One
|
June 22, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
Richard N Greenberg, Christine M Hay, Jack T Stapleton, et al.
Plos One
|
October 7, 2015
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N Greenberg, Maria Yadira Hurley, Yadira Hurley, et al.
Open Forum Infectious Diseases
|
September 18, 2015
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
Edgar Turner Overton, Jack Stapleton, Ian Frank, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 15, 2022
Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients
Emmanuel J Favaloro, Joanne Clifford, Emma Leitinger, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Arthritis and Rheumatism
|
April 29, 2006
Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus
Suzanne Donnelly, Wendy Roake, Simon Brown, et al.
Arthritis Research & Therapy
|
May 30, 2019
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, et al.
Nuclear Medicine and Biology
|
February 17, 2012
Synthesis of ApoSense compound [18F]2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-(fluoromethyl)butanoic acid ([18F]NST732) by nucleophilic ring opening of an aziridine precursor
Falguni Basuli, Haitao Wu, Zhen-Dan Shi, et al.
Frontiers in Medicine
|
June 12, 2023
Characteristics of delirium and its association with sedation and in-hospital mortality in patients with COVID-19 on veno-venous extracorporeal membrane oxygenation
Philip Young-Woo Sun, Jonathon Fanning, Anna Peeler, et al.
Plos One
|
April 14, 2018
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
Edgar Turner Overton, Steven J Lawrence, Eva Wagner, et al.
Research and Practice in Thrombosis and Haemostasis
|
December 19, 2022
Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients
Philip Young-Ill Choi, Danny Hsu, Huyen Anh Tran, et al.
Plos One
|
June 22, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
Richard N Greenberg, Christine M Hay, Jack T Stapleton, et al.
Plos One
|
October 7, 2015
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N Greenberg, Maria Yadira Hurley, Yadira Hurley, et al.
Open Forum Infectious Diseases
|
September 18, 2015
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
Edgar Turner Overton, Jack Stapleton, Ian Frank, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 15, 2022
Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients
Emmanuel J Favaloro, Joanne Clifford, Emma Leitinger, et al.
Page
of 4